ORACEA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORACEA (ORACEA).
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing tRNA-amino acid binding. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and downregulating cytokine production.
| Metabolism | Doxycycline is partially metabolized in the liver via glucuronidation; excreted primarily in feces and urine. Major enzyme involvement is not well defined. |
| Excretion | Primarily renal, with about 60% of a dose excreted unchanged in urine via glomerular filtration; biliary/fecal excretion accounts for approximately 35% as active drug and conjugates. |
| Half-life | Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged in renal impairment (up to 44 hours in severe dysfunction), necessitating dose adjustment for CrCl <30 mL/min. |
| Protein binding | Approximately 40–45% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 1.3 L/kg, indicating extensive distribution into total body water and beyond, with high tissue penetration including skin and mucosal sites. |
| Bioavailability | Oral bioavailability is approximately 95% following a 40 mg capsule, with minimal first-pass metabolism; absorption is not significantly affected by food. |
| Onset of Action | Therapeutic effect begins within 1–2 weeks of oral administration for the treatment of inflammatory lesions of rosacea; noticeable improvement typically by week 3–4. |
| Duration of Action | Dosing interval every 24 hours due to sustained antimicrobial and anti-inflammatory activity; clinical effects persist for several days after discontinuation, but full therapeutic benefit requires continued daily use. |
40 mg orally once daily in the morning, on an empty stomach, at least 1 hour before or 2 hours after meals.
| Dosage form | CAPSULE |
| Renal impairment | No adjustment required for mild to moderate renal impairment. Not recommended in patients with severe renal impairment (CrCl <30 mL/min) or undergoing dialysis. |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients below 9 years of age. For patients ≥9 years: use same adult dosing if indicated for inflammatory lesions of rosacea. |
| Geriatric use | No specific dose adjustment; use caution due to potential for photosensitivity and gastrointestinal effects. Monitor renal function as elderly may have decreased renal reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORACEA (ORACEA).
| Breastfeeding | Doxycycline is excreted into breast milk in small amounts; M/P ratio approximately 0.3-0.4. Theoretical risk of tooth discoloration and bone growth inhibition in nursing infants. The American Academy of Pediatrics considers tetracyclines compatible with breastfeeding, but caution is advised due to possible infant absorption and adverse effects. Alternative antibiotics preferred during lactation. |
| Teratogenic Risk | Doxycycline, the active ingredient in ORACEA, is classified as FDA Pregnancy Category D. First trimester: Avoid due to association with congenital malformations (cardiovascular, neural tube) and inhibition of bone growth. Second/third trimester: Use only if no alternative; associated with permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus due to tetracycline deposition in developing teeth. Also may cause maternal hepatotoxicity and fetal skeletal development delay. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to doxycycline or any tetracycline.","Use in children under 8 years of age except for anthrax or other severe infections."]
| Precautions | ["Use during tooth development (last half of pregnancy, infancy, childhood to age 8 years) may cause permanent tooth discoloration.","Photosensitivity: exaggerated sunburn reaction; avoid prolonged sun exposure.","Potential for Clostridium difficile-associated diarrhea.","Hepatotoxicity reported rarely.","May cause intracranial hypertension.","Use in pregnancy: avoid if possible; tetracyclines can cause fetal harm."] |
Loading safety data…
| Fetal Monitoring | Maternal: Liver function tests (ALT, AST, bilirubin) due to risk of hepatotoxicity; renal function; complete blood count; assess for photosensitivity, GI adverse effects. Fetal: Ultrasound monitoring for skeletal development if exposure in second/third trimester; dental examination postnatally for tooth discoloration. |
| Fertility Effects | Doxycycline has been reported to cause reversible male infertility by impairing sperm motility and density in animal studies; human data are limited but suggest similar effects at high doses. No significant effects on female fertility reported. Use with caution in men planning conception; fertility typically returns after discontinuation. |